USIJ Submits Comments to FTC–DOJ on Drug Pricing and Competition
December 19, 2025
On August 1, 2025, USIJ submitted comments to the Federal Trade Commission as part of the FTC–DOJ listening session on lowering Americans’ drug prices through competition. The submission supports efforts to improve affordability while pushing back against narratives that blame high drug prices on patents and intellectual property protections.
Calls to weaken patent rights — based on claims of “patent thickets” or low-quality patents — are not supported by the evidence and risk undermining the innovation ecosystem that makes new drug development possible. In a market where startups are responsible for more than half of new drug approvals, strong and reliable patent protection remains essential to attracting investment, sustaining high-risk R&D, and delivering life-saving treatments to patients.
USIJ Submits Comments to FTC–DOJ on Drug Pricing and Competition
On August 1, 2025, USIJ submitted comments to the Federal Trade Commission as part of the FTC–DOJ listening session on lowering Americans’ drug prices through competition. The submission supports efforts to improve affordability while pushing back against narratives that blame high drug prices on patents and intellectual property protections.
Calls to weaken patent rights — based on claims of “patent thickets” or low-quality patents — are not supported by the evidence and risk undermining the innovation ecosystem that makes new drug development possible. In a market where startups are responsible for more than half of new drug approvals, strong and reliable patent protection remains essential to attracting investment, sustaining high-risk R&D, and delivering life-saving treatments to patients.